GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05875636

Enrollment

260

Registered

2023-05-25

Start date

2023-08-21

Completion date

2024-08-23

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Content Aspiration

Brief summary

This study will enroll patients ages 18 and over who are in one of the following groups 1) taking a GLP-1 receptor agonist medication 2) not taking a GLP-1 receptor agonist (control group), are undergoing EGS and have appropriately fasted. Study data will be collected in the form of qualitatively observing whether the stomach is empty as expected, or contains solid or clinically relevant liquid contents.

Interventions

OTHEREsophagogastroduodenoscopy

All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults 18 years of age and older presenting for esophagogastroduodenoscopy (EGD) * One of the following groups: * GLP-1 receptor agonist cohort: active treatment with any GLP-1 receptor agonist therapy within prior 30 days * Control cohort: not taking a GLP-1 receptor agonist medication * Appropriately fasted per ASA Fasting Guidelines

Exclusion criteria

* Simultaneous bowel preparation/planned dual endoscopy with colonoscopy * Any pre-planned alteration to standard fasting guidelines (ASA NPO guidelines) * Emergency endoscopic procedure * Concern for active GI bleeding * Food impaction/foreign body as indication for procedure * Gastric outlet obstruction/bowel obstruction * Achalasia * Zenker's diverticulum * History of esophageal or gastric surgery * Active pregnancy * Chronic daily opioid therapy ≥ 15 MMEs per day * Prokinetic agent use (i.e. metoclopramide) * Inability or unwillingness of subject to give informed consent

Design outcomes

Primary

Measure	Time frame	Description
Retained gastric food	From time of enrollment until the end of surgery, assessed up to 4 weeks	Incidence of clinically significant retained gastric food, defined as visible solid/particulate matter, or liquid volume \> 1.5cc/kg

Secondary

Measure	Time frame
Incidence of pulmonary aspiration event	From the time surgery begins until the end of scheduled surgery, assessed up to 24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026